Arrowhead Research Corporation (Arrowhead) is a nanomedicine company engaged in development therapeutic products at the interface of biology and nano-engineering to cure disease and improve human health. Arrowhead is focused on the preclinical and clinical development of therapeutics for the treatment of cancer and obesity, as well as the regeneration of wounded or diseased tissue. Arrowhead�s portfolio includes Calando Pharmaceuticals, Inc. (Calando), delivers small ribonucleic acid (RNA) for gene silencing; and Ablaris Therapeutics, Inc. (Ablaris), an anti-obesity therapeutics company; Nanotope, Inc. (Nanotope), a regenerative medicine company and Leonardo (Leonardo), a multi-stage drug delivery company. In January 2011, its subsidiary, Unidym, Inc., was acquired by Wisepower Co., Ltd. In October 2011, it acquired RNA therapeutics assets from Roche Holding Ltd., including the research site in Madison, WI. In April 2012, it acquired Alvos Therapeutics, Inc.